1. Home
  2. PLSE vs URGN Comparison

PLSE vs URGN Comparison

Compare PLSE & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulse Biosciences Inc (DE)

PLSE

Pulse Biosciences Inc (DE)

HOLD

Current Price

$34.25

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$40.45

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLSE
URGN
Founded
2014
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.0B
IPO Year
2015
2016

Fundamental Metrics

Financial Performance
Metric
PLSE
URGN
Price
$34.25
$40.45
Analyst Decision
Buy
Strong Buy
Analyst Count
1
7
Target Price
$22.00
$29.29
AVG Volume (30 Days)
299.3K
732.8K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,128,000.00
Revenue This Year
$840.00
$129.09
Revenue Next Year
$287.54
$70.96
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.56
$15.86
52 Week High
$36.29
$43.93

Technical Indicators

Market Signals
Indicator
PLSE
URGN
Relative Strength Index (RSI) 65.02 58.18
Support Level $24.27 $18.23
Resistance Level N/A $43.93
Average True Range (ATR) 2.36 2.04
MACD 0.59 -0.35
Stochastic Oscillator 75.81 48.95

Price Performance

Historical Comparison
PLSE
URGN

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: